Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Triggering of the newcastle disease virus fusion protein by a chimeric attachment protein that binds to Nipah virus receptors.

Mirza AM, Aguilar HC, Zhu Q, Mahon PJ, Rota PA, Lee B, Iorio RM.

J Biol Chem. 2011 May 20;286(20):17851-60. doi: 10.1074/jbc.M111.233965. Epub 2011 Apr 1.

2.

Myocarditis caused by human parainfluenza virus in an immunocompetent child initially associated with 2009 influenza A (H1N1) virus.

Romero-Gómez MP, Guereta L, Pareja-Grande J, Martínez-Alarcón J, Casas I, Ruiz-Carrascoso G, de Ory F, Pozo F.

J Clin Microbiol. 2011 May;49(5):2072-3. doi: 10.1128/JCM.02638-10. Epub 2011 Mar 16.

3.

Symptomatic parainfluenza virus infections in children undergoing hematopoietic stem cell transplantation.

Srinivasan A, Wang C, Yang J, Shenep JL, Leung WH, Hayden RT.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1520-7. doi: 10.1016/j.bbmt.2011.03.001. Epub 2011 Mar 9.

4.

Synthetic protocells interact with viral nanomachinery and inactivate pathogenic human virus.

Porotto M, Yi F, Moscona A, LaVan DA.

PLoS One. 2011 Mar 1;6(3):e16874. doi: 10.1371/journal.pone.0016874.

5.

Identification of a natural human serotype 3 parainfluenza virus.

Yang HT, Jiang Q, Zhou X, Bai MQ, Si HL, Wang XJ, Lu Y, Zhao H, He HB, He CQ.

Virol J. 2011 Feb 9;8:58. doi: 10.1186/1743-422X-8-58.

6.

A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality.

Hodson A, Kasliwal M, Streetly M, MacMahon E, Raj K.

Bone Marrow Transplant. 2011 Dec;46(12):1545-50. doi: 10.1038/bmt.2010.347. Epub 2011 Jan 24.

PMID:
21258418
7.

Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry.

Porotto M, Rockx B, Yokoyama CC, Talekar A, Devito I, Palermo LM, Liu J, Cortese R, Lu M, Feldmann H, Pessi A, Moscona A.

PLoS Pathog. 2010 Oct 28;6(10):e1001168. doi: 10.1371/journal.ppat.1001168.

8.

Human parainfluenza virus type 3 (HPIV 3) viral community-acquired pneumonia (CAP) mimicking swine influenza (H1N1) during the swine flu pandemic.

Cunha BA, Corbett M, Mickail N.

Heart Lung. 2011 Jan-Feb;40(1):76-80. doi: 10.1016/j.hrtlng.2010.05.060.

PMID:
20888645
9.

A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.

Moscona A, Porotto M, Palmer S, Tai C, Aschenbrenner L, Triana-Baltzer G, Li QX, Wurtman D, Niewiesk S, Fang F.

J Infect Dis. 2010 Jul 15;202(2):234-41. doi: 10.1086/653621.

10.

Viral entry inhibitors targeted to the membrane site of action.

Porotto M, Yokoyama CC, Palermo LM, Mungall B, Aljofan M, Cortese R, Pessi A, Moscona A.

J Virol. 2010 Jul;84(13):6760-8. doi: 10.1128/JVI.00135-10. Epub 2010 Mar 31.

11.

Hydrophobicity--shake flasks, protein folding and drug discovery.

Sarkar A, Kellogg GE.

Curr Top Med Chem. 2010;10(1):67-83. Review.

12.

Bimolecular complementation of paramyxovirus fusion and hemagglutinin-neuraminidase proteins enhances fusion: implications for the mechanism of fusion triggering.

Connolly SA, Leser GP, Jardetzky TS, Lamb RA.

J Virol. 2009 Nov;83(21):10857-68. doi: 10.1128/JVI.01191-09. Epub 2009 Aug 26.

13.

Human parainfluenza virus infection of the airway epithelium: viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity.

Palermo LM, Porotto M, Yokoyama CC, Palmer SG, Mungall BA, Greengard O, Niewiesk S, Moscona A.

J Virol. 2009 Jul;83(13):6900-8. doi: 10.1128/JVI.00475-09. Epub 2009 Apr 22.

14.

Kinetic dependence of paramyxovirus entry inhibition.

Porotto M, Yokoyama CC, Orefice G, Kim HS, Aljofan M, Mungall BA, Moscona A.

J Virol. 2009 Jul;83(13):6947-51. doi: 10.1128/JVI.00416-09. Epub 2009 Apr 15.

15.

Molecular determinants of antiviral potency of paramyxovirus entry inhibitors.

Porotto M, Carta P, Deng Y, Kellogg GE, Whitt M, Lu M, Mungall BA, Moscona A.

J Virol. 2007 Oct;81(19):10567-74. Epub 2007 Jul 25.

16.

Fusion promotion by a paramyxovirus hemagglutinin-neuraminidase protein: pH modulation of receptor avidity of binding sites I and II.

Palermo LM, Porotto M, Greengard O, Moscona A.

J Virol. 2007 Sep;81(17):9152-61. Epub 2007 Jun 13.

17.
18.

Inhibition of hendra virus fusion.

Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A.

J Virol. 2006 Oct;80(19):9837-49.

19.

Paramyxovirus receptor-binding molecules: engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site.

Porotto M, Fornabaio M, Greengard O, Murrell MT, Kellogg GE, Moscona A.

J Virol. 2006 Feb;80(3):1204-13.

20.

Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.

Madhi SA, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, Murphy BR, Belshe RB, Karron RA, Deatly AM, Gruber WC, Bernstein DI, Wright PF.

Vaccine. 2006 Mar 20;24(13):2432-9. Epub 2005 Dec 20.

PMID:
16406170
Items per page

Supplemental Content

Write to the Help Desk